Navigation Links
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Date:2/1/2012

have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... BioCryst,Pharmaceuticals (Nasdaq: BCRX ) today announced ... Chief Medical Officer of BioCryst, effective July 1,2008. ... recently,serving as Vice President of North American Medical ... Officer Dr. Tom Simon, who has been with,the ...
... use Nuevolution,s Chemetics(R) Technology for Lead Discovery, ... it has entered into a drug discovery collaboration ... its proprietary Chemetics(R) drug discovery,technology to identify novel ... to Merck. The Chemetics(R) platform uses innovative DNA,labeling ...
... Pa., June 17 MEDRAD, INC., announced ... a new Fluorodeoxyglucose (FDG),Infusion System for Positron ... Intego(TM) PET Infusion System is the,first infusion ... automate the FDG,delivery process., (Logo: ...
Cached Biology Technology:William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 3William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 4Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... to Josef Ackermann, the head of Deutsche Bank. At almost ... in Rome. The hand of the manager in charge of ... or security staff have had to conduct painstaking inspections of ... approach. At the end of 2011, though, the scanner T-Cognition ...
... release is available in German . ... from Siegen and Professor Jacek Błażewicz from Poznan have ... (DFG, German Research Foundation) and the Foundation for Polish ... scientific collaboration. "The two researchers perform outstanding research, are ...
... groundbreaking new gene sequencing technology, researchers have demonstrated that ... Acute Myeloid Leukemia, AML, one of the most common ... Pacific Biosciences, allows for the rapid and comprehensive detection ... findings, published online April 15 in Nature , ...
Cached Biology News:On the safe side: Contact-free analysis of chemical substances 2Copernicus Award 2012 for German-Polish collaboration in business information systems 2Copernicus Award 2012 for German-Polish collaboration in business information systems 3Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... product contains 5 ml Dynabeads Tosylactivated (4.5 ... (tosyl) reactive groups. For coupling of antibodies ... on initial coupling with covalent binding of ... sulphydryll groups (SH)) occurringovernight. Coupling reactions can ...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
NAP-2 (5C7)...
Biology Products: